Importantly, glucagon-like peptide-1 (GLP-1) agonists were found to be effective in reducing psoriasis area, severity index, and fasting plasma glucose among patients with psoriasis and diabetes mellitus [31]. This evidence concerns the gene GCG and psoriasis.